在NAFLD中semaglutide作用的演变:在组合,每周和口服中给予
Evgenia Koureta1, Evangelos Cholongitas1
1Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Frontiers in pharmacology
|March 11, 2024
概括
非酒精性脂肪肝 (NAFLD) 是一个日益严重的全球健康问题. 本综述探讨了GLP-1 RA的塞马格卢提德,作为NAFLD的潜在治疗方法,因为它与代谢综合征有共同的途径.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 非酒精性脂肪肝 (NAFLD) 是最常见的慢性肝病.
- 全球范围内NAFLD的患病率正在增加.
- NAFLD与代谢综合征共享病理生理机制.
研究的目的:
- 审查塞马格卢提德在NAFLD的新兴治疗作用.
- 根据其在相关代谢条件中的有效性,讨论塞马格卢提德在管理NAFLD方面的潜力.
主要方法:
- 关于塞马格卢提德,NAFLD和代谢综合征的研究文献综述.
- 分析临床试验数据和机制研究.
- 关于肝脏疾病中的GLP-1受体激动剂的当前证据的综合.
主要成果:
- 作为GLP-1的RA,塞马格卢提德已被批准用于治疗II型糖尿病 (T2DM) 和肥胖症.
- 有证据表明GLP-1RA可能会对肝脏脂肪和炎症产生积极影响.
- 在NAFLD和代谢综合征之间共享的途径支持针对GLP-1.
结论:
- 塞马格卢提德显示出作为NAFLD的新型治疗剂的前景.
- 需要进一步的研究来证实它在NAFLD患者中的有效性和安全性.
- 准代谢途径为NAFLD治疗提供了一个可行的策略.
相关概念视频
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Oral Hypoglycemic Agents: Sulfonylureas
208
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
208
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
175
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
175
Ultrasound II: Endoscopic Ultrasound and FibroScan
105
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
105


